Acasti Pharma, Inc (ACST)

[value1008]

Great news for ACST in Oppenheimer's downgrade of AMRN after-hours today. This is a news blurb from SeekingAlpha.com:

Amarin slips 3% on bearish coverage • 5:08 PM

Oppenheimer initiates Amarin (NASDAQ:AMRN) with an Underperform rating and $7 price target, suggesting a whopping 70% downside from this afternoon's close. Among the negative items: The 12-month stream of late-stage competitor data beginning next month will increasingly weigh on Vascepa (h/t Notable Calls); the idea of Amarin as an M&A target is likely to diminish over time (h/t Marc Lehman). Shares are down 3.9% after hours to $21.85.

Apparently included in the Oppenheimer report is a positive read-through for Acasti Pharma (NASDAQ:ACST), and those shares are up 4.9% after hours